These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35223402)

  • 21. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
    Petrovic N; Sami A; Martinovic J; Zaric M; Nakashidze I; Lukic S; Jovanovic-Cupic S
    Pathol Res Pract; 2017 Oct; 213(10):1264-1270. PubMed ID: 28935174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
    Singla H; Kaur RP; Shafi G; Vashistha R; Banipal RPS; Kumar V; Munshi A
    Mol Biol Rep; 2019 Feb; 46(1):823-831. PubMed ID: 30535550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
    Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis.
    Qiao EQ; Yang HJ; Zhang XP
    J Zhejiang Univ Sci B; 2020 Jun; 21(6):495-508. PubMed ID: 32478495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA LINC-PINT retards the abnormal growth of airway smooth muscle cells via regulating the microRNA-26a-5p/PTEN axis in asthma.
    Gao P; Ding Y; Yin B; Gu H
    Int Immunopharmacol; 2021 Oct; 99():107997. PubMed ID: 34315115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases.
    Xi X; Huang XW; Yuan HZ; He C; Ni J; Yang FL
    Oncol Lett; 2020 Nov; 20(5):273. PubMed ID: 33014152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
    Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
    Liu Z; Wang C; Chen X; Zhu J; Sun X; Xia Q; Lu Z; Qiao J; Zhou Y; Wang H; Wang Y; Yan M
    Eur J Cancer; 2022 Apr; 165():157-168. PubMed ID: 35235873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
    Jung EJ; Santarpia L; Kim J; Esteva FJ; Moretti E; Buzdar AU; Di Leo A; Le XF; Bast RC; Park ST; Pusztai L; Calin GA
    Cancer; 2012 May; 118(10):2603-14. PubMed ID: 22370716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma.
    Shi D; Wang H; Ding M; Yang M; Li C; Yang W; Chen L
    Onco Targets Ther; 2019; 12():6605-6616. PubMed ID: 31496749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.
    Le Scodan R; Jouanneau L; Massard C; Gutierrez M; Kirova Y; Cherel P; Gachet J; Labib A; Mouret-Fourme E
    BMC Cancer; 2011 Sep; 11():395. PubMed ID: 21929800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
    Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
    Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MicroRNA-26a-5p targets Wnt5a to regulate osteogenic differentiation of human periodontal ligament stem cell from inflammatory microenvironment].
    Zhang KK; Geng YD; Wang SB; Huo L
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Oct; 54(10):662-669. PubMed ID: 31607001
    [No Abstract]   [Full Text] [Related]  

  • 38. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
    J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
    Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
    Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.